2025
|
Clonal Hematopoiesis as a Driver of Solid Tumors.
Weeks LD, Ebert BL. N Engl J Med. 2025 Apr 24;392(16):1654-1656. |
| ||
|
Sex differences in DNMT3A-mutant clonal hematopoiesis and the effects of estrogen.
Stomper J, Niroula A, Belizaire R, McConkey M, Bandaru TS, Ebert BL.Cell Rep. 2025 Apr 2;44(4):115494. |
| ||
2024
|
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL).
Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, Olson JE, Rabe KG, Hoel MS, Boddicker NJ, Hampel PJ, Kay NE, Cerhan JR, Braggio E, Hanson CA, Vachon CM, Shanafelt TD, Ebert BL, Slager SL. Blood Cancer J. 2024 Nov 6;14(1):193. |
| ||
|
Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues.
Hassan MM, Li YD, Ma MW, Teng M, Byun WS, Puvar K, Lumpkin R, Sandoval B, Rutter JC, Jin CY, Wang MY, Xu S, Schmoker AM, Cheong H, Groendyke BJ, Qi J, Fischer ES, Ebert BL, Gray NS. Eur J Med Chem. 2024 Sep 24;279:116904. |
| ||
|
JAK2-mutant Clonal Hematopoiesis is Associated with Venous Thromboembolism.
Zon RL, Sekar A, Clapham K, Oren O, Niroula A, Bick AG, Gibson CJ, Griffin GK, Uddin MM, Neuberg DS, Natarajan P, Ebert BL. Blood. 2024 Jul 16:blood.2024024187. |
| ||
|
Template-assisted covalent modification underlies activity of covalent molecular glues.
Li YD, Ma MW, Hassan MM, Hunkeler M, Teng M, Puvar K, Lumpkin R, Sandoval B, Jin CY, Ficarro SB, Wang MY, Xu S, Groendyke BJ, Sigua LH, Tavares I, Zou C, Tsai JM, Park PMC, Yoon H, Majewski FC, Marto JA, Qi J, Nowak RP, Donovan KA, Słabicki M, Gray NS, Fischer ES, Ebert BL. Nat Chem Biol. 2024 Jul 29. |
| ||
|
Polymerization of ZBTB transcription factors regulates chromatin occupancy.
Park PMC, Park J, Brown J, Hunkeler M, Roy Burman SS, Donovan KA, Yoon H, Nowak RP, Słabicki M, Ebert BL, Fischer ES. Mol Cell. 2024 Jul 11;84(13):2511-2524.e8. |
| ||
|
Targeted protein degradation: from mechanisms to clinic.
Tsai JM, Nowak RP, Ebert BL, Fischer ES. Nat Rev Mol Cell Biol. 2024 Apr 29. |
| ||
|
Association of Somatic TET2 Mutations With Giant Cell Arteritis.
Robinette ML, Weeks LD, Kramer RJ, Agrawal M, Gibson CJ, Yu Z, Sekar A, Mehta A, Niroula A, Brown JT, McDermott GC, Reshef ER, Lu JE, Liou VD, Chiou CA, Natarajan P, Freitag SK, Rao DA, Ebert BL. Arthritis Rheumatol. 2024 Mar;76(3):438-443. |
| ||
|
Clonal Hematopoiesis of Indeterminate Potential With Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation.
Lin AE, Bapat AC, Xiao L, Niroula A, Ye J, Wong WJ, Agrawal M, Farady CJ, Boettcher A, Hergott CB, McConkey M, Flores-Bringas P, Shkolnik V, Bick AG, Milan D, Natarajan P, Libby P, Ellinor PT, Ebert BL. Circulation. 2024 Feb 15. |
| ||
|
Induced protein degradation for therapeutics: past, present, and future.
Yoon H, Rutter JC, Li YD, Ebert BL. J Clin Invest. 2024 Jan 2;134(1):e175265. |
| ||
2023
|
Causes and Consequences of Clonal Hematopoiesis.
Weeks LD, Ebert BL. Blood. 2023 Nov 6; 142(26):2235-2246. |
| ||
|
Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes.
Rauch PJ, Gopakumar J, Silver AJ, Nachun D, Ahmad H, McConkey M, Nakao T, Bosse M, Rentz T, Vivanco Gonzalez N, Greenwald NF, McCaffrey EF, Khair Z, Gopakumar M, Rodrigues KB, Lin AE, Sinha E, Fefer M, Cohen DN, Vromman A, Shvartz E, Sukhova G, Bendall S, Angelo M, Libby P, Ebert BL, Jaiswal S. Nat Cardiovasc Res. 2023 Sep;2(9):805-818. |
| ||
|
Design principles for cyclin K molecular glue degraders.
Kozicka Z, Suchyta DJ, Focht V, Kempf G, Petzold G, Jentzsch M, Zou C, Di Genua C, Donovan KA, Coomar S, Cigler M, Mayor-Ruiz C, Schmid-Burgk JL, Häussinger D, Winter GE, Fischer ES, Słabicki M, Gillingham D, Ebert BL, Thomä NH. Nat Chem Biol. 2023 Sep 7. |
| ||
|
Research Briefing:
Unraveling the diversity of molecular glue degraders Kozicka Z and Thomä NH. Nat Chem Biol. 2023 Sep 7. |
| ||
|
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.
Miller PG, Sperling AS, Mayerhofer C, McConkey M, Ellegast JM, Da Silva C, Cohen DN, Wang C, Sharda A, Yan N, Saha S, Schluter C, Schechter IA, Słabicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaier K, Bhatt S, Lindsley RC, Ebert BL. Blood. 2023 Aug 18:blood.2023020331. |
| ||
Editorial:
PPM1D inhibition may allow us to WIP leukemia.
Marcellino BK. Blood. 2023 Dec 14;142(24):2040-2042.
PPM1D inhibition may allow us to WIP leukemia.
Marcellino BK. Blood. 2023 Dec 14;142(24):2040-2042.
|
UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.
Tsai JM, Aguirre JD, Li YD, Brown J, Focht V, Kater L, Kempf G, Sandoval B, Schmitt S, Rutter JC, Galli P, Sandate CR, Cutler JA, Zou C, Donovan KA, Lumpkin RJ, Cavadini S, Park PMC, Sievers Q, Hatton C, Ener E, Regalado BD, Sperling MT, Słabicki M, Kim J, Zon R, Zhang Z, Miller PG, Belizaire R, Sperling AS, Fischer ES, Irizarry R, Armstrong SA, Thomä NH, Ebert BL. Mol Cell. 2023 Aug 3;83(15):2753-2767.e10. |
| ||
Commentary:
To be (in a transcriptional complex) or not to be (promoting UBR5 ubiquitylation): That is an answer to how degradation controls gene expression.
Hehl LA, Schulman BA. Mol Cell. 2023 Aug 3;83(15):2616-2618
To be (in a transcriptional complex) or not to be (promoting UBR5 ubiquitylation): That is an answer to how degradation controls gene expression.
Hehl LA, Schulman BA. Mol Cell. 2023 Aug 3;83(15):2616-2618
|
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein.
Zou C, Yoon H, Park PMC, Patten JJ, Pellman J, Carreiro J, Tsai JM, Li YD, Roy Burman SS, Donovan KA, Gasser J, Sperling AS, Nowak RP, Fischer ES, Davey RA, Ebert BL, Słabicki M. iScience. 2023 May 19;26(5):106601. |
| ||
|
Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
Weeks LD, Niroula A, Neuberg D, Wong W, Lindsley RC, Luskin MR, Berliner N, Stone RM, DeAngelo DJ, Soiffer RJ, Uddin MM, Griffin G, Vlasschaert C, Gibson CJ, Jaiswal S, Bick AG, Malcovati L, Natarajan P, Ebert BL. NEJM Evid. 2023 May;2(5):10.1056/evidoa2200310. |
| ||
Commentary:
How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide.
Xie, Z and DeZern, AE. NEJM Evid. 2023;2(5)
How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide.
Xie, Z and DeZern, AE. NEJM Evid. 2023;2(5)
|
Clonal haematopoiesis and risk of chronic liver disease.
Wong WJ, Emdin C, Bick AG, Zekavat SM, Niroula A, Pirruccello JP, Dichtel L, Griffin G, Uddin MM, Gibson CJ, Kovalcik V, Lin AE, McConkey ME, Vromman A, Sellar RS, Kim PG, Agrawal M, Weinstock J, Long MT, Yu B, Banerjee R, Nicholls RC, Dennis A, Kelly M, Loh PR, McCarroll S, Boerwinkle E, Vasan RS, Jaiswal S, Johnson AD, Chung RT, Corey K, Levy D, Ballantyne C; NHLBI TOPMed Hematology Working Group; Ebert BL, Natarajan P. Nature. 2023 Apr;616(7958):747-754. |
| ||
Commentary:
Elucidating the link between clonal haematopoiesis and chronic liver disease.
Hindson J. Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):345.
Elucidating the link between clonal haematopoiesis and chronic liver disease.
Hindson J. Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):345.
Clonal haematopoiesis and dysregulation of the immune system.
Belizaire R, Wong WJ, Robinette ML, Ebert BL. Nat Rev Immunol. 2023 Sep;23(9):595-610. Review.
Belizaire R, Wong WJ, Robinette ML, Ebert BL. Nat Rev Immunol. 2023 Sep;23(9):595-610. Review.
2022
|
Clonal Hematopoiesis of Indeterminate Potential and Risk of Death from COVID-19.
Miller P, Fell G, Foy B, Scherer A, Gibson CJ, Sperling AS, Burugula BB, Nakao T, Uddin MM, Warren H, Bry L, Pozdnyakova O, Frigault MJ, Bick AG, Neuberg D, Higgins JM, Mansour M, Natarajan P, Kim AS, Kitzman J, Ebert BL. Blood. 2022 Nov 3;140(18):1993-1997. |
| ||
|
Clonal hematopoiesis transcending species barriers.
Rauch PJ, Ebert BL. Blood. 2022 Oct 20;140(16):1748-1750. Commentary |
| ||
|
A STUB1 ubiquitin ligase/CHIC2 protein complex negatively regulates the IL-3, IL-5, and GM-CSF cytokine receptor common β chain (CSF2RB) protein stability.
Koochaki SHJ, Słabicki M, Lumpkin R, Zou C, Belizaire R, Fischer ES, Ebert BL. J Biol Chem. 2022 Oct;298(10):102484. |
| ||
|
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little LD, Gumbs CE, Daver NG, DiNardo CD, Kadia TM, Ravandi F, Kantarjian HM, Garcia-Manero G, Futreal A, Ebert BL, Takahashi K. Blood. 2022 Oct 20;140(16):1753-1763. |
| ||
Comment:
Connecting the dots: lenalidomide and t-MNs.
Chakraborty S, Park CY. Blood. 2022 Oct 20;140(16):1745-1747.
Connecting the dots: lenalidomide and t-MNs.
Chakraborty S, Park CY. Blood. 2022 Oct 20;140(16):1745-1747.
|
TET2-mutant clonal hematopoiesis and risk of gout.
Agrawal M, Niroula A, Cunin P, McConkey M, Kovalcik V, Kim PG, Wong WJ, Weeks LD, Lin AE, Miller PG, Gibson CJ, Sekar A, Schaefer IM, Neuberg D, Stone RM, Bick AG, Uddin MM, Griffin GK, Jaiswal S, Natarajan P, Nigrovic PA, Rao DA, Ebert BL. Blood. 2022 Sep 8;140(10):1094-1103. |
| ||
Editorial:
CHIP and gout: trained immunity?
Merriman TR, Joosten LAB. Blood. 2022 Sep 8;140(10):1054-1056.
CHIP and gout: trained immunity?
Merriman TR, Joosten LAB. Blood. 2022 Sep 8;140(10):1054-1056.
|
Degradation of GSPT1 causes TP53-independent cell death in leukemia whilst sparing normal hematopoietic stem cells.
Sellar RS, Sperling AS, Słabicki M, Gasser JA, McConkey ME, Donovan KA, Mageed N, Adams DN, Zou C, Miller PG, Dutta RK, Boettcher S, Lin AE, Sandoval BE, Quevedo Barrios VA, Shkolnik V, Koeppel J, Henderson EK, Fink EC, Yang L, Chan AK, Pokharel SP, Bergstrom EJ, Burt R, Udeshi ND, Carr SA, Fischer ES, Chen CW, Ebert BL. J Clin Invest. 2022 Aug 15;132(16):e153514. |
| ||
|
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.
Miller PG, Sathappa M, Moroco JA, Jiang W, Qian Y, Iqbal S, Guo Q, Giacomelli AO, Shaw S, Vernier C, Bajrami B, Yang X, Raffier C, Sperling AS, Gibson CJ, Kahn J, Jin C, Ranaghan M, Caliman A, Brousseau M, Fischer ES, Lintner R, Piccioni F, Campbell AJ, Root DE, Garvie CW, Ebert BL. Nat Commun. 2022 Jun 30;13(1):3778. |
| ||
Blood's life history traced through genomic scars.
Sekar A, Ebert BL. Nature. 2022 Jun;606(7913):255-256. Commentary
Sekar A, Ebert BL. Nature. 2022 Jun;606(7913):255-256. Commentary
|
Genetic barcoding systematically comparing genes in del(5q) MDS reveals a central role for CSNK1A1 in clonal expansion.
Stalmann USA, Ticconi F, Snoeren IAM, Li R, Gleitz H, Cowley G, McConkey ME, Wong AB, Schmitz S, Fuchs SNR, Sood S, Leimkühler NB, Martinez-Høyer S, Banjanin B, Root DE, Brümmendorf TH, Pearce J, Schuppert A, Bindels E, Essers M, Heckl D, Stiehl TP, Costa IG, Ebert BL, Schneider RK. Blood Adv. 2022 Mar 22;6(6):1780-1796. |
| ||
|
Leukemia and Heart Disease: Lessons at the Intersection of the Most Feared CHIP Outcomes.
Rauch PJ, Ebert BL. JACC CardioOcol 2022 Mar 15;4(1):50-52. Editorial |
| ||
|
Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Weeks LD, Marinac CR, Redd R, Abel G, Lin A, Agrawal M, Stone RM, Schrag D, Ebert BL. Blood. 2022 Feb 24;139(8):1246-1250. |
| ||
|
Association of clonal hematopoiesis with chronic obstructive pulmonary disease.
Miller PG, Qiao D, Rojas-Quintero J, Honigberg MC, Sperling AS, Gibson CJ, Bick AG, Niroula A, McConkey ME, Sandoval B, Miller BC, Shi W, Viswanathan K, Leventhal M, Werner L, Moll M, Cade BE, Barr RG, Correa A, Cupples LA, Gharib SA, Jain D, Gogarten SM, Lange LA, London SJ, Manichaikul A, O'Connor GT, Oelsner EC, Redline S, Rich SS, Rotter JI, Ramachandran V, Yu B, Sholl L, Neuberg D, Jaiswal S, Levy BD, Owen CA, Natarajan P, Silverman EK, van Galen P, Tesfaigzi Y, Cho MH, Ebert BL; COPDGene Study Investigators, National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium.Blood. 2022 Jan 20;139(3):357-368 |
| ||
| |||
2021
|
Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis.
Kim PG, Niroula A, Shkolnik V, McConkey M, Lin AE, Słabicki M, Kemp JP, Bick A, Gibson CJ, Griffin G, Sekar A, Brooks DJ, Wong WJ, Cohen DN, Uddin MM, Shin WJ, Pirruccello J, Tsai JM, Agrawal M, Kiel DP, Bouxsein ML, Richards JB, Evans DM, Wein MN, Charles JF, Jaiswal S, Natarajan P, Ebert BL. J Exp Med. 2021 Dec 6;218(12):e20211872. |
| ||
| |||
Distinction of lymphoid and myeloid clonal hematopoiesis.
Niroula A, Sekar A, Murakami MA, Trinder M, Agrawal M, Wong WJ, Bick AG, Uddin MM, Gibson CJ, Griffin GK, Honigberg MC, Zekavat SM, Paruchuri K, Natarajan P, Ebert BL. Nat Med. 2021 Nov;27(11):1921-1927.
Niroula A, Sekar A, Murakami MA, Trinder M, Agrawal M, Wong WJ, Bick AG, Uddin MM, Gibson CJ, Griffin GK, Honigberg MC, Zekavat SM, Paruchuri K, Natarajan P, Ebert BL. Nat Med. 2021 Nov;27(11):1921-1927.
|
ZBTB33 is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing.
Beauchamp EM, Leventhal M, Bernard E, Hoppe ER, Todisco G, Creignou M, Gallì A, Castellano CA, McConkey M, Tarun A, Wong W, Schenone M, Stanclift C, Tanenbaum B, Malolepsza E, Nilsson B, Bick AG, Weinstock JS, Miller M, Niroula A, Dunford A, Taylor-Weiner A, Wood T, Barbera A, Anand S, Psaty BM, Desai P, Cho MH, Johnson AD, Loos R; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, MacArthur DG, Lek M; Exome Aggregation Consortium, Neuberg DS, Lage K, Carr SA, Hellstrom-Lindberg E, Malcovati L, Papaemmanuil E, Stewart C, Getz G, Bradley RK, Jaiswal S, Ebert BL. Blood Cancer Discov. 2021 Sep;2(5):500-517. |
| ||
|
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.
Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, Gohil SH, Tai YT, Munshi NC, Wu CJ, Neuberg DS, Maus MV, Jacobson C, Gibson CJ, Ebert BL. Blood Adv. 2021 Aug 10;5(15):2982-2986. |
| ||
|
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, De Botton S, Kiladjian JJ, Cayuela JM, Rolfe M, Chamberlain PP, Carr SA, Ebert BL. Blood Cancer Discov. 2021 May;2(3):250-265. |
| ||
Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.
Jan M, Sperling AS, Ebert BL. Nat Rev Clin Oncol. 2021 Mar 2.
Jan M, Sperling AS, Ebert BL. Nat Rev Clin Oncol. 2021 Mar 2.
|
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.
Tothova Z, Valton AL, Gorelov R, Vallurupalli M, Krill-Burger JM, Holmes A, Landers CC, Haydu JE, Malolepsza E, Hartigan CR, Donahue M, Popova KD, Koochaki SHJ, Venev SV, Rivera JF, Chen E, Lage K, Schenone M, D'Andrea AD, Carr SA, Morgan EA, Dekker J, Ebert BL. JCI Insight. 2021 Feb 8;6(3):e142149. |
| ||
|
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Belizaire R, Koochaki SHJ, Udeshi ND, Vedder A, Sun L, Svinkina T, Hartigan C, McConkey ME, Kovalcik V, Bizuayehu A, Stanclift C, Schenone M, Carr SA, Padron E, Ebert BL. Blood. 2021 Jan 7:blood.2020006528. |
| ||
|
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.
Jan M, Scarfò I, Larson RC, Walker A, Schmidts A, Guirguis AA, Gasser JA, Słabicki M, Bouffard AA, Castano AP, Kann MC, Cabral ML, Tepper A, Grinshpun DE, Sperling AS, Kyung T, Sievers QL, Birnbaum ME, Maus MV, Ebert BL. Sci Transl Med. 2021 Jan 6;13(575):eabb6295. |
| ||
2020
|
Small-molecule-induced polymerization triggers degradation of BCL6.
Słabicki M, Yoon H, Koeppel J, Nitsch L, Roy Burman SS, Di Genua C, Donovan KA, Sperling AS, Hunkeler M, Tsai JM, Sharma R, Guirguis A, Zou C, Chudasama P, Gasser JA, Miller PG, Scholl C, Fröhling S, Nowak RP, Fischer ES, Ebert BL. Nature. 2020 Nov 18. Companion Video Small-molecule-induced Protein Polymerization. 2020 Nov 18. |
| ||
|
Contribution of Clonal Hematopoiesis to Adult-Onset Hemophagocytic Lymphohistiocytosis.
Miller P, Sperling AS, Gibson CJ, Viswanathan K, Castellano CA, McConkey ME, Ceremsak JJ, Taylor MS, Birndt S, Perner F, Arnason JE, Agrawal M, Schram A, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL. Blood. 2020 Sep 22:blood.2020008206. |
| ||
|
Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade.
Miller PG, Gibson CJ, Mehta A, Sperling AS, Frederick DT, Manos MP, Miao B, Hacohen N, Hodi FS, Boland GM, Ebert BL. JCO Precis Oncol. 2020 Sep 9;4:PO.20.00186. |
| ||
|
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.
Słabicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, Donovan KA, Sievers QL, Koeppel J, Suchyta D, Sperling AS, Fink EC, Gasser JA, Wang LR, Corsello SM, Sellar RS, Jan M, Gillingham D, Scholl C, Fröhling S, Golub TR, Fischer ES, Thomä NH, Ebert BL. Nature. 2020 Sep;585(7824):293-297. |
| ||
Commentary
Prospecting for molecular glues.
den Besten W, Lipford JR. Nat Chem Biol. 2020 Aug 3.
Companion Articles
Molecular glue degraders – a new weapon to target “undruggable” cancer drivers.
NCT Nationales Centrum für Tumorerkrankungen Heidelberg. Accessed 2020 September 22.
Researchers discover new member of novel drug family for ‘undruggable’ targets
Davis, N. 2020 June 04. Broad Institute News.
Companion Video
CR8 is a novel molecular glue degrader. 2020 Oct 7
Prospecting for molecular glues.
den Besten W, Lipford JR. Nat Chem Biol. 2020 Aug 3.
Companion Articles
Molecular glue degraders – a new weapon to target “undruggable” cancer drivers.
NCT Nationales Centrum für Tumorerkrankungen Heidelberg. Accessed 2020 September 22.
Researchers discover new member of novel drug family for ‘undruggable’ targets
Davis, N. 2020 June 04. Broad Institute News.
Companion Video
CR8 is a novel molecular glue degrader. 2020 Oct 7
|
Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia.
Hasserjian RP, Steensma DP, Graubert TA, Ebert BL. Blood. 2020 Mar 13:blood.2019004770. |
| ||
|
Identification of germline variants in adults with hemophagocytic lymphohistiocytosis.
Miller PG, Niroula A, Ceremsak JJ, Gibson CJ, Taylor MS, Birndt S, Perner F, Arnason J, Sperling AS, Agrawal M, Schram AM, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL. Blood Adv. 2020 Mar 10;4(5):925-929. |
| ||
|
Clonal hematopoiesis as a model for premalignant changes during aging.
Steensma DP, Ebert BL. Exp Hematol. 2020 Mar;83:48-56. |
| ||
|
A new opening on aortic stenosis: predicting prognosis with clonal haematopoiesis.
Lin AE, Libby P, Ebert BL.Eur Heart J. 2020 Feb 21;41(8):940-942. |
| ||
2019
|
Clonal hematopoiesis in human aging and disease.
Jaiswal S, Ebert BL. Science. 2019 Nov 1;366(6465). |
| ||
| |||
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. Science. 2019 Aug 9;365(6453):599-604.
Commentary:
How to lose tumor suppression.
Lane DP. Science. 2019 Aug 9;365(6453):539-540.
Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. Science. 2019 Aug 9;365(6453):599-604.
Commentary:
How to lose tumor suppression.
Lane DP. Science. 2019 Aug 9;365(6453):539-540.
|
Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.
Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, Zeiher A, Jaiswal S, Schulz C, Blankstein R, Bolton KL, Steensma D, Levine RL, Ebert BL. J Am Coll Cardiol. 2019 Jul 30;74(4):567-577. |
| ||
|
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.
Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Lindsley RC, Ebert BL. Blood Adv. 2019 Jul 23;3(14):2199-2204. |
| ||
|
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
DeZern AE, Malcovati L, Ebert BL. Am Soc Clin Oncol Educ Book. 2019 Jan;39:400-410. |
| ||
|
Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs.
Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL. Blood 2019 Jul 11. |
| ||
Commentary:
The Pandora's box of thalidomide analogs and their substrates.
Neri P. Blood. 2019 Jul 11;134(2):105-106.
The Pandora's box of thalidomide analogs and their substrates.
Neri P. Blood. 2019 Jul 11;134(2):105-106.
CHIPping Away at the Pathogenesis of Heart Failure.
Libby P, Jaiswal S, Lin AE, Ebert BL. JAMA Cardiol 2019 Jan 1.
Libby P, Jaiswal S, Lin AE, Ebert BL. JAMA Cardiol 2019 Jan 1.
2018
|
Jak-ing Up the Plaque's Lipid Core…and Even More.
Libby P, Molinaro R, Sellar RS, Ebert BL. Circ Res 2018 Nov 9;123(11):1180-1182. |
| ||
|
Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia.
Ebert BL, Krönke J. N Engl J Med 2018 Nov 8;379(19):1873-1874. |
| ||
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL, Petzold G, Bunker RD, Renneville A, Słabicki M, Liddicoat BJ, Abdulrahman W, Mikkelsen T, Ebert BL, Thomä NH. Science 2018 Nov 2;362(6414).
Commentary:
Evolving Rules for Protein Degradation? Insights from the Zinc Finger Degrome.
Buhimschi AD, Crews CM. Biochemistry. 2019 Feb 19;58(7):861-864.
Sievers QL, Petzold G, Bunker RD, Renneville A, Słabicki M, Liddicoat BJ, Abdulrahman W, Mikkelsen T, Ebert BL, Thomä NH. Science 2018 Nov 2;362(6414).
Commentary:
Evolving Rules for Protein Degradation? Insights from the Zinc Finger Degrome.
Buhimschi AD, Crews CM. Biochemistry. 2019 Feb 19;58(7):861-864.
|
CHIP (Clonal Hematopoiesis of Indeterminate Potential).
Libby P, Ebert BL. Circulation 2018 Aug 14;138(7):666-668. |
| ||
| |||
|
Crbn(I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.
Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, Udeshi ND, Mani DR, Chen M, Liddicoat B, Svinkina T, Nguyen AT, Carr SA, Ebert BL. Blood 2018 Jul 31. |
| ||
|
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4-CRBN activity.
Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Blood 2018 Jul 24. |
| ||
| |||
|
PPM1D truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.
Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Mar B, Mertins P, Fereshetian S, Krug K, Zhu H, Letai A, Carr SA, Doench J, Jaiswal S, Ebert BL. Blood 2018 Jun 28. |
| ||
Commentary:
CHIPing out PPM1D-mutant hematopoiesis.
Kindler T. Blood 2018 Sep 13;132(11):1087-1088.
CHIPing out PPM1D-mutant hematopoiesis.
Kindler T. Blood 2018 Sep 13;132(11):1087-1088.
Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers.
Ebert, BL, Libby, P. Ann Intern Med 2018 Jul 17;169(2):116-117.
Ebert, BL, Libby, P. Ann Intern Med 2018 Jul 17;169(2):116-117.
|
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Wolach, O, Sellar, RS, Martinod, K, Cherpokova, D, McConkey, M, Chappell, RJ, Silver, AJ, Adams, D, Castellano, CA, Schneider, RK, Padera, RF, DeAngelo, DJ, Wadleigh, M, Steensma, DP, Galinsky, I, Stone, RM, Genovese, G, McCarroll, SA, Iliadou, B, Hultman, C, Neuberg, D, Mullally, A, Wagner, DD, Ebert, BL. Sci Trans Med 2018 Apr 11;10(436). |
| ||
|
Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.
Steensma, DP and Ebert, BL. N Engl J Med 2018 Mar 29;378(13):1244-1245. |
| ||
2017
|
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL. Blood 2017 130:2631-2641. |
| ||
Commentary:
SETD2: a complex role in blood malignancy.
Licht JD. Blood 2017 Dec 14;130(24):2576-2578.
SETD2: a complex role in blood malignancy.
Licht JD. Blood 2017 Dec 14;130(24):2576-2578.
|
Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.
Tothova Z, Krill-Burger JM, Popova KD, Landers CC, Sievers QL, Yudovich D, Belizaire R, Aster JC, Morgan EA, Tsherniak A, Ebert BL. Cell Stem Cell 2017 21(4):547-555.e8. |
|
| ||||
Commentary:
E Pluribus Unum ("Out of Many, One"): CRISPR Modeling of Myeloid Expansion.
Shin J, Corn JE. Cell Stem Cell 2017 Oct 5;21(4):415-416.
E Pluribus Unum ("Out of Many, One"): CRISPR Modeling of Myeloid Expansion.
Shin J, Corn JE. Cell Stem Cell 2017 Oct 5;21(4):415-416.
|
Leukaemia: Vitamin C regulates stem cells and cancer.
Miller PG, Ebert BL. Nature 2017 Sep 28;549(7673):462-464. |
| ||
| |||
|
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. N Engl J Med 2017 377(2):111-121. |
| ||
Editorial:
CHIP-ping Away at Atherosclerosis.
Keaney JF Jr. N Engl J Med 2017 Jul 13;377(2):184-185.
CHIP-ping Away at Atherosclerosis.
Keaney JF Jr. N Engl J Med 2017 Jul 13;377(2):184-185.
|
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL. J Clin Oncol. 2017 May 10;35(14):1598-1605. |
| ||
|
Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations.
Ajore R, Raiser D, McConkey M, Jöud M, Boidol B, Mar B, Saksena G, Weinstock DM, Armstrong S, Ellis SR, Ebert BL, Nilsson B. EMBO Mol Med 2017 Apr;9(4):498-507. |
| ||
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
Kennedy JA, Ebert BL. J Clin Oncol 2017 Mar 20;35(9):968-974. Review.
Kennedy JA, Ebert BL. J Clin Oncol 2017 Mar 20;35(9):968-974. Review.
|
Doubling Down on Mutant RAS Can MEK or Break Leukemia.
Tothova Z, Ebert BL. Cell 2017 Feb 23;168(5):749-750. Review. |
| ||
|
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. N Engl J Med 2017 Feb 9;376(6):536-547. |
| ||
| |||
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
Sperling AS, Gibson CJ, Ebert BL. Nat Rev Cancer 2017 Jan;17(1):5-19. Review.
Sperling AS, Gibson CJ, Ebert BL. Nat Rev Cancer 2017 Jan;17(1):5-19. Review.
2016
|
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, Schneider RK, Lord AM, Wang L, Gambe RG, McConkey ME, Ali AM, Raza A, Yu L, Buonamici S, Smith PG, Mullally A, Wu CJ, Fleming MD, Ebert BL. Cancer Cell 2016 Sep 12;30(3):404-417. |
| ||
|
Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.
Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, Tothova Z, Tejero H, Heckl D, Järås M, Chen MC, Li H, Tamayo A, Cowley GS, Rozenblatt-Rosen O, Al-Shahrour F, Regev A, Ebert BL. Cell 2016 Apr 7;165(2):303-16. |
| ||
Editorial:
A Time Bomb for Leukemia.
Maryanovich M, Frenette PS. Cell 2016 Apr 7;165(2):262-3. editorial.
A Time Bomb for Leukemia.
Maryanovich M, Frenette PS. Cell 2016 Apr 7;165(2):262-3. editorial.
|
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, Brümmendorf TH, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL. Nat Med 2016 Mar;22(3):288-97. |
| ||||
2015
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Guirguis AA, Ebert BL. Curr Opin Cell Biol 2015 Dec; 37:61-7. Review.
Guirguis AA, Ebert BL. Curr Opin Cell Biol 2015 Dec; 37:61-7. Review.
|
The novel mechanism of lenalidomide activity.
Fink EC, Ebert BL. Blood 2015 Nov 19;126(21):2366-9. Review. |
| ||
|
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.
Renneville A, Van Galen P, Canver MC, McConkey M, Krill-Burger JM, Dorfman DM, Holson EB, Bernstein BE, Orkin SH, Bauer DE, Ebert BL. Blood 2015 Oct 15;126(16):1930-9. |
| ||
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Nature. 2015 Jul 9;523(7559):183-188.
Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Nature. 2015 Jul 9;523(7559):183-188.
Commentary:
Myeloid disease: Another action of a thalidomide derivative.
Ito T, Handa H. Nature 2015 Jul 9;523(7559):167-8.
Myeloid disease: Another action of a thalidomide derivative.
Ito T, Handa H. Nature 2015 Jul 9;523(7559):167-8.
|
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Blood 2015 Jul 2;126(1):9-16. |
| ||
Commentary:
Clonal hematopoiesis: a "CHIP" off the old block.
Lichtman MA. Blood 2015 Jul 2;126(1):1-2.
Clonal hematopoiesis: a "CHIP" off the old block.
Lichtman MA. Blood 2015 Jul 2;126(1):1-2.
Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation.
Esrick EB, McConkey M, Lin K, Frisbee A, Ebert BL. Am J Hematol 2015 Jul;90(7):624-8.
Esrick EB, McConkey M, Lin K, Frisbee A, Ebert BL. Am J Hematol 2015 Jul;90(7):624-8.
|
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.
Okam MM, Esrick EB, Mandell E, Campigotto F, Neuberg DS, Ebert BL. Blood 2015 Jun 4;125(23):3668-9. |
| ||
| |||
|
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Blood 2015 Feb 26;125(9):1367-76. |
| ||
2014
|
Age-related clonal hematopoiesis associated with adverse outcomes.
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. N Engl J Med 2014 Dec 25;371(26):2488-98. |
| ||
Commentary:
Clone wars--the emergence of neoplastic blood-cell clones with aging.
Abkowitz JL. N Engl J Med 2014 Dec 25;371(26):2523-5.
Clone wars--the emergence of neoplastic blood-cell clones with aging.
Abkowitz JL. N Engl J Med 2014 Dec 25;371(26):2523-5.
|
Human genetics: somatic mutations linked to future disease risk.
Burgess DJ. Nat Rev Genet 2015 Feb;16(2):69. |
| ||
|
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL. Blood 2014 Oct 23;124(17):2705-12. |
| ||
|
Commentary:
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Lee EJ, Zeidan AM. Expert Rev Hematol 2015 Apr;8(2):155-8. |
| ||
|
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Cancer Cell 2014 Oct 13;26(4):509-20. |
| ||
Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.
Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL. Nat Biotechnol 2014 Sep;32(9):941-6.
Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL. Nat Biotechnol 2014 Sep;32(9):941-6.
|
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL. J Clin Oncol 2014 Sep 1;32(25):2691-8. |
| ||
|
Lenalidomide induces degradation of IKZF1 and IKZF3.
Krönke J, Hurst SN, Ebert BL. Oncoimmunology 2014 Jul 3;3(7):e941742. |
| ||
|
MDS is a stem cell disorder after all.
Jaiswal S, Ebert BL. Cancer Cell 2014 Jun 16;25(6):713-4. Commentary. |
| ||
|
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.
Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL. J Exp Med 2014 Apr 7;211(4):605-12. |
| ||
|
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA. Nat Commun 2014 Mar 24;5:3469. |
| ||
The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders.
Raiser DM, Narla A, Ebert BL. Leuk Lymphoma 2014 Mar;55(3):491-500.
Raiser DM, Narla A, Ebert BL. Leuk Lymphoma 2014 Mar;55(3):491-500.
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Science 2014 Jan 17;343(6168):301-5.
Perspective:
Medicine. How thalidomide works against cancer.
Stewart AK. Science 2014 Jan 17;343(6168):256-7.
Preview:
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.
Licht JD, Shortt J, Johnstone R. Cancer Cell 2014 Jan 13;25(1):9-11.
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Science 2014 Jan 17;343(6168):301-5.
Perspective:
Medicine. How thalidomide works against cancer.
Stewart AK. Science 2014 Jan 17;343(6168):256-7.
Preview:
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.
Licht JD, Shortt J, Johnstone R. Cancer Cell 2014 Jan 13;25(1):9-11.
2013
|
The biology and clinical impact of genetic lesions in myeloid malignancies.
Lindsley RC, Ebert BL. Blood 2013 Nov 28;122(23):3741-8. |
| ||
|
Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.
Mullally A, Ebert BL. Cell Stem Cell 2013 Sep 5;13(3):257-8. |
| ||
|
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.
Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, Jordan CT, Ebert BL. Cancer Cell 2013 Jul 8;24(1):45-58. |
| ||
|
Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
Steensma DP, Ebert BL. Blood 2013 May 23;121(21):4428. |
| ||
|
New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.
Tothova Z, Steensma DP, Ebert BL. Clin Cancer Res 2013 Apr 1;19(7):1637-43. |
| ||
Molecular pathophysiology of myelodysplastic syndromes.
Lindsley RC, Ebert BL. Annu Rev Pathol 2013 Jan 24;8:21-47. Review.
Lindsley RC, Ebert BL. Annu Rev Pathol 2013 Jan 24;8:21-47. Review.
2012
Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma.
Mullally A, Ebert BL. J Clin Oncol 2012 Nov 20;30(33):4168-70.
Mullally A, Ebert BL. J Clin Oncol 2012 Nov 20;30(33):4168-70.
|
Myeloproliferative neoplasm animal models.
Mullally A, Lane SW, Brumme K, Ebert BL. Hematol Oncol Clin North Am 2012 Oct;26(5):1065-81. Review. |
| ||
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. J Clin Oncol 2012 Sep 20;30(27):3376-82.
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. J Clin Oncol 2012 Sep 20;30(27):3376-82.
|
Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Blood 2012 Jul 5;120(1):166-72. |
| ||
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM, Ebert BL. Expert Rev Hematol 2012 Jun;5(3):303-11.
Okam MM, Ebert BL. Expert Rev Hematol 2012 Jun;5(3):303-11.
|
Pulmonary fibrosis, bone marrow failure, and telomerase mutation.
Gansner JM, Rosas IO, Ebert BL. N Engl J Med 2012 Apr 19;366(16):1551-3. |
| ||
Commentary:
Telomerase mutations and the pulmonary fibrosis-bone marrow failure syndrome complex.
Armanios M. N Engl J Med 2012 Jul 26;367(4):384; author reply 384.
Telomerase mutations and the pulmonary fibrosis-bone marrow failure syndrome complex.
Armanios M. N Engl J Med 2012 Jul 26;367(4):384; author reply 384.
2011
|
Power cut: inhibiting mitochondrial translation to target leukemia.
Järås M, Ebert BL. Cancer Cell 2011 Nov 15;20(5):555-6. |
| ||
|
Translational medicine: ribosomopathies.
Narla A, Ebert BL. Blood 2011 Oct 20;118(16):4300-1. |
| ||
|
Molecular dissection of the 5q deletion in myelodysplastic syndrome.
Ebert BL. Semin Oncol 2011 Oct;38(5):621-6. Review. |
| ||
|
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. Blood 2011 Oct 27;118(17):4666-73. |
| ||
|
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
Narla A, Dutt S, McAuley JR, Al-Shahrour F, Hurst S, McConkey M, Neuberg D, Ebert BL. Blood 2011 Aug 25;118(8):2296-304. |
| ||
| |||
|
Clinical effect of point mutations in myelodysplastic syndromes.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. N Engl J Med 2011 Jun 30;364(26):2496-506. |
| ||
|
Commentary:
The dawn of the molecular era of the myelodysplastic syndromes. Odenike, O, Le Beau MM. N Engl J Med 2011 Jun 30;364(26):2545-6. |
| ||
|
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Blood 2011 Mar 3;117(9):2567-76. |
| ||
| |||
Ribosome defects in disorders of erythropoiesis.
Narla A, Hurst SN, Ebert BL. Int J Hematol 2011 Feb;93(2):144-149. Review.
Narla A, Hurst SN, Ebert BL. Int J Hematol 2011 Feb;93(2):144-149. Review.
|
Densely interconnected transcriptional circuits control cell states in human hematopoiesis.
Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, Habib N, Yosef N, Chang CY, Shay T, Frampton GM, Drake AC, Leskov I, Nilsson B, Preffer F, Dombkowski D, Evans JW, Liefeld T, Smutko JS, Chen J, Friedman N, Young RA, Golub TR, Regev A, Ebert BL. Cell. 2011 Jan 21;144(2):296-309. |
| ||
|
Commentary:
A comprehensive transcriptional landscape of human hematopoiesis. Kee BL. Cell Stem Cell 2011 Feb 4;8(2):122-4. |
| ||
Unraveling the molecular pathophysiology of myelodysplastic syndromes.
Bejar R, Levine R, Ebert BL. J Clin Oncol 2011 Feb 10;29(5):504-15. Review.
Bejar R, Levine R, Ebert BL. J Clin Oncol 2011 Feb 10;29(5):504-15. Review.
2010
|
Genetic deletions in AML and MDS.
Ebert BL. Best Pract Res Clin Haematol. 2010 Dec;23(4):457-61. Review. |
| ||
|
STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation.
Mullally A, Ebert BL. Cancer Cell 2010 Nov 16;18(5):405-6. |
| ||
|
NF1 inactivation revs up Ras in adult acute myelogenous leukemia.
Mullally A, Ebert BL. Clin Cancer Res 2010 Aug 15;16(16):4074-6. Review. |
| ||
|
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.
Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, DeAngelo DJ, Carr SA, Schreiber SL, Golub TR, Ebert BL. Proc Natl Acad Sci USA 2010 Jul 13;107(28):12617-22. |
| ||
|
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Cancer Cell 2010 Jun 15;17(6):584-96. |
| ||
|
Commentary:
The molecular biology of myeloproliferative disorders. Radich J. Cancer Cell 2010 Jul 13;18(1):7-8. |
| ||
|
The genetic basis of myelodysplastic syndromes.
Bejar R, Ebert BL. Hematol Oncol Clin North Am 2010 Apr;24(2):295-315. Review. |
| ||
|
Ribosomopathies: human disorders of ribosome dysfunction.
Narla A, Ebert BL. Blood 2010 Apr 22;115(16):3196-205. Review. |
| ||
2009
Therapeutic potential of targeting haploinsufficient genes in cancer.
Cheung KJ, Ebert BL. Pediatr Blood Cancer 2009 Aug;53(2):131-2. Review.
Cheung KJ, Ebert BL. Pediatr Blood Cancer 2009 Aug;53(2):131-2. Review.
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.
Ebert BL. Leukemia 2009 Jul;23(7):1252-6.
Ebert BL. Leukemia 2009 Jul;23(7):1252-6.
|
Ultrasome: efficient aberration caller for copy number studies of ultra-high resolution.
Nilsson B, Johansson M, Al-Shahrour F, Carpenter AE, Ebert BL. Bioinformatics 2009 Apr 15;25(8):1078-9. |
| ||
2008
|
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A. PLoS Med 2008 Feb;5(2):e35. |
| ||
| |||
|
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR. Nature 2008 Jan 17;451(7176):335-9. |
| ||
|
Commentary:
Cancer: hay in a haystack. Shannon KM, Le Beau MM. Nature 2008 Jan 17;451(7176):252-3. |
| ||